SLDB

SEC source: 0000899243-22-037693 · doc4.xml · nonDerivative · entry 1

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 356,380

F1 · price: The reporting person acquired 13,172 shares of the issuer's common stock pursuant to the issuer's acquisition of all of the outstanding capital stock of AavantiBio, Inc. on December 2, 2022.

SEC source: 0000899243-22-037688 · doc4.xml · derivative · entry 2

Marlowe Jennifer · CIK 0001955871 · CSO, FA & Cardiac

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,555

Underlying: Common Stock · 47,555 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock (the "RSUs").

F3 · derivative.exercise_date: The RSUs were granted on the Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

F3 · derivative.expiration_date: The RSUs were granted on the Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

SEC source: 0000899243-22-037688 · doc4.xml · derivative · entry 1

Marlowe Jennifer · CIK 0001955871 · CSO, FA & Cardiac

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 95,110

Underlying: Common Stock · 95,110 shares

Expires 2032-12-02

F1 · derivative.exercise_date: This option was granted on December 2, 2022 (the "Grant Date") and vests over four years, with 25% of the original number of shares vesting on the first anniversary of the Grant Date and 2.0833% of the original number of shares on the first day of each calendar month thereafter until the fourth such anniversary.

SEC source: 0000899243-22-037686 · doc4.xml · derivative · entry 2

Howton David T · CIK 0001529297 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,205

Underlying: Common Stock · 52,205 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock (the "RSUs").

F3 · derivative.exercise_date: The RSUs were granted on the Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

F3 · derivative.expiration_date: The RSUs were granted on the Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

SEC source: 0000899243-22-037686 · doc4.xml · derivative · entry 1

Howton David T · CIK 0001529297 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 104,410

Underlying: Common Stock · 104,410 shares

Expires 2032-12-02

F1 · derivative.exercise_date: This option was granted on December 2, 2022 (the "Grant Date") and vests over four years, with 25% of the original number of shares vesting on the first anniversary of the Grant Date and 2.0833% of the original number of shares on the first day of each calendar month thereafter until the fourth such anniversary.

SEC source: 0000899243-22-037684 · doc4.xml · derivative · entry 2

Herzich Paul · CIK 0001954991 · Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,955

Underlying: Common Stock · 28,955 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock (the "RSUs").

F3 · derivative.exercise_date: The RSUs were granted on the Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

F3 · derivative.expiration_date: The RSUs were granted on the Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

SEC source: 0000899243-22-037684 · doc4.xml · derivative · entry 1

Herzich Paul · CIK 0001954991 · Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,900

Underlying: Common Stock · 57,900 shares

Expires 2032-12-02

F1 · derivative.exercise_date: This option was granted on December 2, 2022 (the "Grant Date") and vests over four years, with 25% of the original number of shares vesting on the first anniversary of the Grant Date and 2.0833% of the original number of shares on the first day of each calendar month thereafter until the fourth such anniversary.

SEC source: 0000899243-22-037682 · doc4.xml · derivative · entry 2

Hanrahan Jessie · CIK 0001954826 · Chief Regulatory Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,449

Underlying: Common Stock · 47,449 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock (the "RSUs").

F3 · derivative.exercise_date: The RSUs were granted on the Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

F3 · derivative.expiration_date: The RSUs were granted on the Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

SEC source: 0000899243-22-037682 · doc4.xml · derivative · entry 1

Hanrahan Jessie · CIK 0001954826 · Chief Regulatory Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 94,899

Underlying: Common Stock · 94,899 shares

Expires 2032-12-02

F1 · derivative.exercise_date: This option was granted on December 2, 2022 (the "Grant Date") and vests over four years, with 25% of the original number of shares vesting on the first anniversary of the Grant Date and 2.0833% of the original number of shares on the first day of each calendar month thereafter until the fourth such anniversary.

SEC source: 0000899243-22-037681 · doc4.xml · derivative · entry 3

Cumbo Alexander · CIK 0001685994 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 114,449

Underlying: Common Stock · 114,449 shares

Expires not disclosed

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock (the "RSUs").

F4 · derivative.exercise_date: The RSUs were granted on the Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

F4 · derivative.expiration_date: The RSUs were granted on the Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

SEC source: 0000899243-22-037681 · doc4.xml · derivative · entry 2

Cumbo Alexander · CIK 0001685994 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 228,900

Underlying: Common Stock · 228,900 shares

Expires 2032-12-02

F2 · derivative.exercise_date: This option was granted on December 2, 2022 (the "Grant Date") and vests over four years, with 25% of the original number of shares vesting on the first anniversary of the Grant Date and 2.0833% of the original number of shares on the first day of each calendar month thereafter until the fourth such anniversary.

SEC source: 0000899243-22-037681 · doc4.xml · nonDerivative · entry 1

Cumbo Alexander · CIK 0001685994 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 584

F1 · price: The reporting person acquired 584 shares of the issuer's common stock pursuant to the issuer's acquisition of all of the outstanding capital stock of AavantiBio, Inc. on December 2, 2022.

SEC source: 0000899243-22-037648 · doc4.xml · derivative · entry 1

Koppel Adam · CIK 0001578965 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,666

Underlying: Common Stock · 2,666 shares

Expires 2032-12-01

F1 · derivative.exercise_date: This option was granted on December 2, 2022 and vests in full on the one-year anniversary of the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.

SEC source: 0001104659-22-124599 · tm2232018-1_4seq1.xml · nonDerivative · entry 3

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director · 10% owner

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 109,661

F4 · price: Acquired pursuant to the acquisition by the Issuer of AavantiBio, Inc. ("AavantiBio") in exchange for shares of preferred stock of AavantiBio pursuant to the Agreement and Plan of Merger dated September 29, 2022.

F5 · ownership.nature: Held directly by RA Capital Nexus Fund, L.P. (the "Nexus Fund").

F6 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and the Nexus Fund. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0001104659-22-124599 · tm2232018-1_4seq1.xml · nonDerivative · entry 2

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director · 10% owner

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 3,288,056

F4 · price: Acquired pursuant to the acquisition by the Issuer of AavantiBio, Inc. ("AavantiBio") in exchange for shares of preferred stock of AavantiBio pursuant to the Agreement and Plan of Merger dated September 29, 2022.

F2 · balance_after: Reflects the Issuer's reverse stock split that occurred on October 27, 2022.

F3 · ownership.nature: Held directly by RA Capital Healthcare Fund, L.P. (the "Fund").

F6 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and the Nexus Fund. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0001104659-22-124599 · tm2232018-1_4seq1.xml · nonDerivative · entry 1

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director · 10% owner

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 2,987,644

F1 · price: Acquired from the Issuer pursuant to the Securities Purchase Agreement dated September 29, 2022.

F2 · balance_after: Reflects the Issuer's reverse stock split that occurred on October 27, 2022.

F3 · ownership.nature: Held directly by RA Capital Healthcare Fund, L.P. (the "Fund").

F6 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and the Nexus Fund. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0001062993-22-023430 · form4.xml · nonDerivative · entry 3

PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner

PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · Director · 10% owner

Perceptive Xontogeny Venture Fund, LP · CIK 0001757940 · Director · 10% owner

Perceptive Venture Advisors, LLC · CIK 0001890130 · Director · 10% owner

EDELMAN JOSEPH · CIK 0001164426 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 73,107

F4 · price: Acquired pursuant to the acquisition by the Issuer of AavantiBio, Inc. ("AavantiBio") in exchange for shares of preferred stock of AavantiBio pursuant to the Agreement and Plan of Merger dated September 29, 2022.

F5 · ownership.nature: The securities are directly held by Perceptive Xontogeny Venture Fund, LP ("Perceptive Xontogeny"). Perceptive Venture Advisors, LLC (the "Venture Advisor") serves as the investment advisor to Perceptive Xontogeny and is an affiliate of the Advisor. Mr. Joseph Edelman is the managing member of the Advisor. The Venture Advisor, the Advisor and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes.

SEC source: 0001062993-22-023430 · form4.xml · nonDerivative · entry 2

PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner

PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · Director · 10% owner

Perceptive Xontogeny Venture Fund, LP · CIK 0001757940 · Director · 10% owner

Perceptive Venture Advisors, LLC · CIK 0001890130 · Director · 10% owner

EDELMAN JOSEPH · CIK 0001164426 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 3,422,826

F4 · price: Acquired pursuant to the acquisition by the Issuer of AavantiBio, Inc. ("AavantiBio") in exchange for shares of preferred stock of AavantiBio pursuant to the Agreement and Plan of Merger dated September 29, 2022.

F2 · balance_after: Reflects the Issuer's reverse stock split that occurred on October 27, 2022.

F3 · ownership.nature: The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager to the Master Fund. Mr. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.

SEC source: 0001062993-22-023430 · form4.xml · nonDerivative · entry 1

PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner

PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · Director · 10% owner

Perceptive Xontogeny Venture Fund, LP · CIK 0001757940 · Director · 10% owner

Perceptive Venture Advisors, LLC · CIK 0001890130 · Director · 10% owner

EDELMAN JOSEPH · CIK 0001164426 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 3,057,290

F1 · price: Acquired from the Issuer pursuant to the Securities Purchase Agreement dated September 29, 2022.

F2 · balance_after: Reflects the Issuer's reverse stock split that occurred on October 27, 2022.

F3 · ownership.nature: The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager to the Master Fund. Mr. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.

SEC source: 0001209191-22-052331 · doc4.xml · derivative · entry 2

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,312

Underlying: Common Stock · 24,312 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F2 · derivative.exercise_date: The restricted stock units were granted on January 3, 2022 and vest in equal quarterly installments beginning three months from the date of the grant, with the final installment vesting 12 months from the date of the grant, subject to continued service as a director, and in the event of a change in control, the vesting schedule of the award will accelerate in full.

F2 · derivative.expiration_date: The restricted stock units were granted on January 3, 2022 and vest in equal quarterly installments beginning three months from the date of the grant, with the final installment vesting 12 months from the date of the grant, subject to continued service as a director, and in the event of a change in control, the vesting schedule of the award will accelerate in full.

SEC source: 0001209191-22-052331 · doc4.xml · nonDerivative · entry 1

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 343,208

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

SEC source: 0001209191-22-041164 · doc4.xml · derivative · entry 2

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,624

Underlying: Common Stock · 24,313 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F2 · derivative.exercise_date: The restricted stock units were granted on January 3, 2022 and vest in equal quarterly installments beginning three months from the date of the grant, with the final installment vesting 12 months from the date of the grant, subject to continued service as a director, and in the event of a change in control, the vesting schedule of the award will accelerate in full.

F2 · derivative.expiration_date: The restricted stock units were granted on January 3, 2022 and vest in equal quarterly installments beginning three months from the date of the grant, with the final installment vesting 12 months from the date of the grant, subject to continued service as a director, and in the event of a change in control, the vesting schedule of the award will accelerate in full.

SEC source: 0001209191-22-041164 · doc4.xml · nonDerivative · entry 1

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 318,896

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

SEC source: 0001062993-22-014589 · form4.xml · derivative · entry 1

PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner

EDELMAN JOSEPH · CIK 0001164426 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 51,000

Underlying: Common Stock · 51,000 shares

Expires 2032-06-07

F1 · derivative.exercise_date: This option was granted on June 7, 2022 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.

F2 · ownership.nature: Consists of options to purchase shares of the Issuer's common stock awarded to Adam Stone in connection with his role as a member of the Issuer's Board of Directors. Mr. Stone is the Chief Investment Officer of Perceptive Advisors, LLC (the "Advisor"). The Advisor may be deemed to have an indirect pecuniary interest in the options to purchase common stock of the Issuer reported herein because the Advisor has the right to receive the director compensation provided in respect of Mr. Stone's board service through a partial management fee offset.

F3 · ownership.nature: Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.

SEC source: 0001062993-22-014590 · form4.xml · derivative · entry 1

Stone Adam Leo · CIK 0001727440 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,000

Underlying: Common Stock · 51,000 shares

Expires 2032-06-07

F1 · derivative.exercise_date: This option was granted on June 7, 2022 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.

SEC source: 0001209191-22-035433 · doc4.xml · derivative · entry 1

Huffines Robert Luther · CIK 0001728221 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,000

Underlying: Common Stock · 51,000 shares

Expires 2032-06-07

F1 · derivative.exercise_date: This option was granted on June 7, 2022 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.

SEC source: 0001104659-22-069744 · tm2218093-1_4seq1.xml · derivative · entry 1

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 51,000

Underlying: Common Stock · 51,000 shares

Expires 2032-06-07

F2 · derivative.exercise_date: This option was granted on June 7, 2022 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the issuers next annual meeting of stockholdings occurring after the grant date and will vest automaticall as to 100% of the unvested portion of such option upon specified change in control events.

F1 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

F2 · ownership.nature: This option was granted on June 7, 2022 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the issuers next annual meeting of stockholdings occurring after the grant date and will vest automaticall as to 100% of the unvested portion of such option upon specified change in control events.

F3 · ownership.nature: Under Mr. Shah's arrangement with the Adviser, Mr. Shah holds the option for the benefit of the Fund. Mr. Shah is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock except to the extent of their pecuniary interest.

SEC source: 0001209191-22-035465 · doc4.xml · derivative · entry 1

Sullivan Lynne Marie · CIK 0001727640 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,000

Underlying: Common Stock · 51,000 shares

Expires 2032-06-07

F1 · derivative.exercise_date: This option was granted on June 7, 2022 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.

SEC source: 0001209191-22-035463 · doc4.xml · derivative · entry 1

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,000

Underlying: Common Stock · 51,000 shares

Expires 2032-06-07

F1 · derivative.exercise_date: This option was granted on June 7, 2022 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.

SEC source: 0001209191-22-035461 · doc4.xml · derivative · entry 1

Nagendran Sukumar · CIK 0001665124 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,000

Underlying: Common Stock · 51,000 shares

Expires 2032-06-07

F1 · derivative.exercise_date: This option was granted on June 7, 2022 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.

SEC source: 0001209191-22-035459 · doc4.xml · derivative · entry 1

Keresty Georgia · CIK 0001773532 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,000

Underlying: Common Stock · 51,000 shares

Expires 2032-06-07

F1 · derivative.exercise_date: This option was granted on June 7, 2022 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.

SEC source: 0001209191-22-035457 · doc4.xml · derivative · entry 2

Kahn Clare · CIK 0001849236 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2032-06-07

F2 · derivative.exercise_date: This option was granted on June 7, 2022 and vests in equal quarterly installments over the 12 month period following the grant date, subject to continued service as a director or consultant.

SEC source: 0001209191-22-035457 · doc4.xml · derivative · entry 1

Kahn Clare · CIK 0001849236 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,000

Underlying: Common Stock · 51,000 shares

Expires 2032-06-07

F1 · derivative.exercise_date: This option was granted on June 7, 2022 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.

SEC source: 0001209191-22-035427 · doc4.xml · derivative · entry 1

Freed Martin I · CIK 0001676653 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,000

Underlying: Common Stock · 51,000 shares

Expires 2032-06-07

F1 · derivative.exercise_date: This option was granted on June 7, 2022 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.

SEC source: 0001209191-22-027115 · doc4.xml · derivative · entry 1

Ganot Ilan · CIK 0001727460 · Director · CEO & President

10b5-1 filing: Not disclosed

Ownership: Indirect · Spouse

Disclosed balance after: 46,600

Underlying: Common Stock · 46,600 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuers common stock.

F2 · derivative.exercise_date: The restricted stock units were granted on May 2, 2022 and vest in two equal annual installments beginning on the first anniversary of the grant date.

F2 · derivative.expiration_date: The restricted stock units were granted on May 2, 2022 and vest in two equal annual installments beginning on the first anniversary of the grant date.

SEC source: 0001209191-22-027118 · doc4.xml · derivative · entry 1

Morris Carl Ashley · CIK 0001727571 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 296,000

Underlying: Common Stock · 296,000 shares

Expires 2032-05-02

F1 · derivative.exercise_date: This option was granted on May 2, 2022 and vests in three equal annual installments beginning on the first anniversary of the grant date.

SEC source: 0001209191-22-027108 · doc4.xml · derivative · entry 1

Brennan Erin Powers · CIK 0001764644 · Chief Legal Officer, Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 254,000

Underlying: Common Stock · 254,000 shares

Expires 2032-05-02

F1 · derivative.exercise_date: This option was granted on May 2, 2022 and vests in three equal annual installments beginning on the first anniversary of the grant date.

SEC source: 0001209191-22-023040 · doc4.xml · derivative · entry 2

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 72,937

Underlying: Common Stock · 24,313 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F2 · derivative.exercise_date: The restricted stock units were granted on January 3, 2022 and vest in equal quarterly installments beginning three months from the date of the grant, with the final installment vesting 12 months from the date of the grant, subject to continued service as a director, and in the event of a change in control, the vesting schedule will accelerate in full.

F2 · derivative.expiration_date: The restricted stock units were granted on January 3, 2022 and vest in equal quarterly installments beginning three months from the date of the grant, with the final installment vesting 12 months from the date of the grant, subject to continued service as a director, and in the event of a change in control, the vesting schedule will accelerate in full.

SEC source: 0001209191-22-023040 · doc4.xml · nonDerivative · entry 1

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 294,583

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

SEC source: 0001209191-22-018885 · doc4.xml · nonDerivative · entry 2

Morris Carl Ashley · CIK 0001727571 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 255,209

F1 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units. The shares were sold pursuant to a written instruction under Rule 10b5-1(c)(1).

SEC source: 0001209191-22-018885 · doc4.xml · nonDerivative · entry 1

Morris Carl Ashley · CIK 0001727571 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 266,605

F1 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units. The shares were sold pursuant to a written instruction under Rule 10b5-1(c)(1).

F2 · balance_after: Includes 2,272 shares acquired by Mr. Morris under the Solid Biosciences Employee Stock Purchase Plan on November 30, 2021.

SEC source: 0001209191-22-018883 · doc4.xml · nonDerivative · entry 2

Schneider Joel Solomon Zev · CIK 0001727649 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 236,270

F1 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units. The shares were sold pursuant to a written instruction under Rule 10b5-1(c)(1).

SEC source: 0001209191-22-018883 · doc4.xml · nonDerivative · entry 1

Schneider Joel Solomon Zev · CIK 0001727649 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 251,542

F1 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units. The shares were sold pursuant to a written instruction under Rule 10b5-1(c)(1).

F2 · balance_after: Reflects a correction as to the number of securities previously reported in Column 5 of Table I due to an arithmetical error.

SEC source: 0001209191-22-017114 · doc4.xml · nonDerivative · entry 1

Ganot Ilan · CIK 0001727460 · Director · CEO & President

10b5-1 filing: Not disclosed

Ownership: Indirect · Wife

Disclosed balance after: 2,518

F1 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units. The shares were sold pursuant to a written instruction under Rule 10b5-1(c)(1).

SEC source: 0001209191-22-005690 · doc4.xml · derivative · entry 4

Ganot Ilan · CIK 0001727460 · Director · CEO & President

10b5-1 filing: Not disclosed

Ownership: Indirect · Wife

Disclosed balance after: 23,300

Underlying: Common Stock · 23,300 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuers common stock.

F3 · derivative.exercise_date: The restricted stock units were granted on January 27, 2022 and vest on the same schedule as set forth in footnote (1) above.

F3 · derivative.expiration_date: The restricted stock units were granted on January 27, 2022 and vest on the same schedule as set forth in footnote (1) above.

SEC source: 0001209191-22-005690 · doc4.xml · derivative · entry 3

Ganot Ilan · CIK 0001727460 · Director · CEO & President

10b5-1 filing: Not disclosed

Ownership: Indirect · Wife

Disclosed balance after: 46,400

Underlying: Common Stock · 46,400 shares

Expires 2032-01-27

F1 · derivative.exercise_date: This option was granted on January 27, 2022 and vests in four equal annual installments on the anniversary of the grant date.

SEC source: 0001209191-22-005690 · doc4.xml · derivative · entry 2

Ganot Ilan · CIK 0001727460 · Director · CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 233,000

Underlying: Common Stock · 233,000 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuers common stock.

F3 · derivative.exercise_date: The restricted stock units were granted on January 27, 2022 and vest on the same schedule as set forth in footnote (1) above.

F3 · derivative.expiration_date: The restricted stock units were granted on January 27, 2022 and vest on the same schedule as set forth in footnote (1) above.

SEC source: 0001209191-22-005690 · doc4.xml · derivative · entry 1

Ganot Ilan · CIK 0001727460 · Director · CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 466,000

Underlying: Common Stock · 466,000 shares

Expires 2032-01-27

F1 · derivative.exercise_date: This option was granted on January 27, 2022 and vests in four equal annual installments on the anniversary of the grant date.

SEC source: 0001209191-22-005693 · doc4.xml · derivative · entry 2

Morris Carl Ashley · CIK 0001727571 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 74,000

Underlying: Common Stock · 74,000 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuers common stock.

F3 · derivative.exercise_date: The restricted stock units were granted on January 27, 2022 and vest on the same schedule as set forth in footnote (1) above.

F3 · derivative.expiration_date: The restricted stock units were granted on January 27, 2022 and vest on the same schedule as set forth in footnote (1) above.

SEC source: 0001209191-22-005693 · doc4.xml · derivative · entry 1

Morris Carl Ashley · CIK 0001727571 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 148,000

Underlying: Common Stock · 148,000 shares

Expires 2032-01-27

F1 · derivative.exercise_date: This option was granted on January 27, 2022 and vests in four equal annual installments on the anniversary of the grant date.